Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Better Biotech
  4.  » 
  5. Biologics
  6.  » Accelerated Pathways from Development to Clinic and Market

Accelerated Pathways from Development to Clinic and Market

Summary: While accelerated development programs are intense by design, few have a similar regulatory experience—particularly when it comes to Breakthrough Therapy Designation (BTD). In this executive summary, industry experts from Alnylam® Pharmaceuticals, Mirum Pharmaceuticals, Catalent Biologics and UroGen® Pharma share case studies of how they’ve adapted to increasingly expedited regulatory reviews.

 

Click here to download the Executive Summary